Search

Gaston R Picchio

from San Diego, CA
Age ~62
Get Report
Also known as:
Gaston Matilde Picchio, Gaston R Piccio, Picchio Gaston
Phone and address:
3987 Santa Nella Pl, San Diego, CA 92130
Related to:
Marcos R Picchio, 34Delfina I Picchio, 27Camila A PicchioCamila A Picchio, 31Matilde Picchio, 59
Connected to:
Barbara A Picchio, 78Gina L Picchiotti, 39Jacob L Picchione, 50John V Picchioni, 92Louis M Picchione, 48Michael L Picchione, 48Teresa L Picchioni, 72Marie E Picci, 54Amy L Picciano, 47Deanine L Picciano, 52

Gaston Picchio Phones & Addresses

  • 3987 Santa Nella Pl, San Diego, CA 92130
  • 34 Pony Ln, Flemington, NJ 08822 (908) 806-3306 (908) 642-0012
  • 18 Cummington Ln, Flemington, NJ 08822 (908) 806-3306
  • Solana Beach, CA
  • La Jolla, CA
  • Raritan, NJ
  • 34 Pony Ln, Flemington, NJ 08822 (908) 642-0012

Work

Position: Homemaker

Education

Degree: High school graduate or higher

Publications

Us Patents

Therapeutic Regimen Comprising Peg-Interferon, Ribavirin And Vx-950 For The Treatment Of Hepatitis

View page
US Patent:
20110236351, Sep 29, 2011
Filed:
Mar 24, 2011
Appl. No.:
13/070991
Inventors:
Robert S. Kauffman - Chestnut Hill MA, US
Cyrill Jean Camille Titeux - Noisy le Roi, FR
Ramon Polo - Basking Ridge NJ, US
Rudolf Peter Gerhardt Van Heeswijk - Beerse, BE
Maria Gloria Beumont - Bievres, FR
Gaston Rafael Picchio - Flemington NJ, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 38/21
A61P 31/20
US Classification:
424 857, 424 854
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.

Hcv Combination Therapies Comprising Pegylated Interferon, Ribavirin And Telaprevir

View page
US Patent:
20120039850, Feb 16, 2012
Filed:
Aug 11, 2011
Appl. No.:
13/207773
Inventors:
Lindsay McNair - Allston MA, US
Robert S. Kauffman - Chestnut Hill MA, US
John J. Alam - Cambridge MA, US
Ramon Polo - Basking Ridge NJ, US
Gaston Rafael Picchio - Flemington NJ, US
Maria Gloria Beumont - Issy Les Moulineaux, FR
Assignee:
Janssen Pharmaceutica NV - Beerse
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 38/21
A61P 31/14
US Classification:
424 857, 424 854
Abstract:
The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.

Therapeutic Regimen Comprising Peg-Interferon, Ribavirin And Vx-950 For The Treatment Of Hepatitis

View page
US Patent:
20130101554, Apr 25, 2013
Filed:
Dec 18, 2012
Appl. No.:
13/718608
Inventors:
ROBERT S. KAUFFMAN - Chestnut Hill MA, US
Cyril Jean Camille Titeux - Vienna, AT
Ramon Polo - Basking Ridge NJ, US
Rudolf Peter Gerhardt Van Heeswijk - Beerse, NL
Maria Gloria Beumont - Issy Les Moulineaux, FR
Gaston Rafael Picchio - Flemington NJ, US
Assignee:
Vertex Pharmaceutical Incorporated - Cambridge MA
International Classification:
A61K 38/21
A61K 38/07
A61K 31/7056
US Classification:
424 857, 424 854
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.

Telaprevir Dosing Regimen

View page
US Patent:
20110165119, Jul 7, 2011
Filed:
Jun 10, 2009
Appl. No.:
12/996650
Inventors:
Maria Gloria Beumont - Issy Les Moulineaux, FR
Stefan Rikard Herdinius - Mechelen, BE
Gaston Rafael Picchio - Yardley PA, US
Ramon Polo - Yardley PA, US
Robert S. Kauffman - Chestnut Hill MA, US
Bambang S. Adiwijaya - Belmont MA, US
Varun Garg - Framingham MA, US
International Classification:
A61K 38/21
A61P 31/14
US Classification:
424 854
Abstract:
This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin.

Method Of Providing Safe Administration Of Adenoviral Vectors Encoding A Zika Virus Antigen

View page
US Patent:
20210113682, Apr 22, 2021
Filed:
Nov 11, 2020
Appl. No.:
17/095183
Inventors:
- Titusville NJ, US
- Boston MA, US
Gaston Rafael PICCHIO - Flemington NJ, US
International Classification:
A61K 39/12
A61K 47/69
A61P 31/14
A61K 9/00
Abstract:
Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.

Method Of Providing Safe Administration Of Adenoviral Vectors Encoding A Zika Virus Antigen

View page
US Patent:
20190151434, May 23, 2019
Filed:
Nov 19, 2018
Appl. No.:
16/194868
Inventors:
- Titusville NJ, US
- Boston MA, US
Gaston Rafael PICCHIO - Flemington NJ, US
International Classification:
A61K 39/12
A61K 9/00
A61K 47/69
A61P 31/14
Abstract:
Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.

Combination Therapy Regimen For Treatment Of Selected Hcv Genotypes

View page
US Patent:
20180021360, Jan 25, 2018
Filed:
Jul 21, 2017
Appl. No.:
15/656821
Inventors:
- Titusville NJ, US
- New Haven CT, US
Lawrence M. Blatt - S. San Francisco CA, US
Sushmita Mukherjee Chanda - S.San Francisco CA, US
John Fry - S.South San Francisco CA, US
Eugene Jans - Beerse, BE
Thomas Naoki Kakuda - S.San Francisco CA, US
Sivi Mahadevan - Ravels, BE
Roel Mertens - Beerse, BE
Gaston Rafael Picchio - San Diego CA, US
Alex Van Dijck - Beerse, BE
Peter Van Remoortere - Princeton NJ, US
David Apelian - Boonton NJ, US
Dawei Chen - Guilford CT, US
Milind Deshphande - Madison CT, US
James Hui - Apex NC, US
Avinash Phadke - Branford CT, US
Assignee:
Janssen Pharmaceuticals, Inc. - Titusville NJ
Achillion Pharmaceuticals, Inc. - New Haven CT
International Classification:
A61K 31/7072
A61K 31/4184
A61K 45/06
A61K 9/48
A61K 9/20
A61K 9/00
A61K 31/4709
A61K 9/14
Abstract:
A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.

Combination Drug Treatment For Hepatitis C Infection

View page
US Patent:
20180021361, Jan 25, 2018
Filed:
Jul 21, 2017
Appl. No.:
15/656872
Inventors:
- Titusville NJ, US
- Haven CT, US
Lawrence M. Blatt - S. San Francisco CA, US
Sushmita Mukherjee Chanda - S.San Francisco CA, US
John Fry - S.South San Francisco CA, US
Eugene Jans - Beerse, BE
Thomas Naoki Kakuda - S.San Francisco CA, US
Sivi Mahadevan - Ravels, BE
Roel Mertens - Beerse, BE
Gaston Rafael Picchio - San Diego CA, US
Alex Van Dijck - Beerse, BE
Peter Van Remoortere - Princeton NJ, US
David Apelian - Boonton NJ, US
Dawei Chen - Guilford CT, US
Milind Deshphande - Madison CT, US
James Hui - Apex NC, US
Avinash Phadke - Branford CT, US
Assignee:
JANSSEN PHARMACEUTICALS, INC. - Titusville NJ
ACHILLION PHARMACEUTICALS, INC. - New Haven CT
International Classification:
A61K 31/7072
A61K 31/416
A61K 9/20
A61K 31/4709
Abstract:
A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
Control profile
Gaston R Picchio from San Diego, CA, age ~62 Get Report